Works matching IS 21534888 AND DT 2019 AND VI 10 AND IP 1
Results: 31
Trump Administration Moves to Curb Drug Rebates in Medicare, Medicaid: Proposal, likely to draw industry resistance, would limit rebates drugmakers give to third parties.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 1, p. 42
- By:
- Publication type:
- Article
Ibrutinib Superior to Standard Chemoimmunotherapy in Older Patients with CLL.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 1, p. 41
- Publication type:
- Article
Hospital Readmissions for Venous Thromboembolism a Substantial Cost in Patients with Cancer.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 1, p. 41
- By:
- Publication type:
- Article
Economic Implications of Inpatient versus Outpatient Autologous Transplant for Patients with Multiple Myeloma.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 1, p. 40
- By:
- Publication type:
- Article
Olaparib Maintenance Extends Progression-Free Survival in Advanced Ovarian Cancer.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 1, p. 39
- Publication type:
- Article
Inpatient Costs for Children and Young Adults with Acute Lymphoblastic Leukemia Higher at Specialized Cancer Centers, but for a Good Reason?
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 1, p. 39
- By:
- Publication type:
- Article
Tisagenlecleucel Leads to High Rates of Durable Response in Relapsed, Refractory DLBCL.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 1, p. 38
- Publication type:
- Article
Oral Rigosertib plus Azacitidine Combination Shows Promising Results in High-Risk Myelodysplastic Syndromes.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 1, p. 31
- By:
- Publication type:
- Article
Luspatercept, First-in-Class Erythroid Maturation Agent, Reduces Transfusions in Patients with Low-Risk Myelodysplastic Syndromes.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 1, p. 30
- By:
- Publication type:
- Article
Elotuzumab, Lenalidomide, and Dexamethasone Combination Demonstrates High Response Rate in High-Risk Smoldering Multiple Myeloma.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 1, p. 29
- By:
- Publication type:
- Article
Daratumumab Enhances Remissions When Added to Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 1, p. 28
- By:
- Publication type:
- Article
Results from the Phase 3 iLLUMINATE Study . . .
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 1, p. 27
- Publication type:
- Article
Ibrutinib 7-Year Follow-Up Data in First-Line and Relapsed/Refractory Patients with CLL/SLL.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 1, p. 27
- Publication type:
- Article
Frontline Ibrutinib Treatment Is Associated with Lower Total Cost of Care Compared with Chemoimmunotherapy in Patients with CLL.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 1, p. 27
- Publication type:
- Article
Results from the Phase 3 iLLUMINATE Study: Ibrutinib plus Obinutuzumab as First-Line Treatment in Patients with CLL/SLL.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 1, p. 26
- Publication type:
- Article
Ibrutinib Alone or in Combination with Rituximab Produces Superior PFS Compared with Bendamustine plus Rituximab in Untreated Older Patients with CLL.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 1, p. 26
- Publication type:
- Article
Phase 3 MURANO Study Explores Potential for Venetoclax-Rituximab Combination Therapy in Relapsed/ Refractory CLL.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 1, p. 23
- Publication type:
- Article
Dual-Specific CAR T-Cell Therapy Targets CD19 and CD22 in Patients with Acute Lymphoblastic Leukemia.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 1, p. 25
- By:
- Publication type:
- Article
Selinexor a Promising Oral Option in Triple-Class Refractory Multiple Myeloma.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 1, p. 24
- By:
- Publication type:
- Article
AMG 420, a Novel BiTE, Shows Impressive Responses in Heavily Treated Patients with Multiple Myeloma.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 1, p. 24
- By:
- Publication type:
- Article
First-Line Ibrutinib Improves Outcomes Compared with Current Standard of Care in Older Patients with Chronic Lymphocytic Leukemia.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 1, p. 23
- By:
- Publication type:
- Article
First-Line Enasidenib Achieves Complete Remission in Older Patients with Acute Myeloid Leukemia and IDH2 Mutation.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 1, p. 19
- By:
- Publication type:
- Article
Researchers Identify First Mutation to Explain Resistance to Venetoclax.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 1, p. 18
- By:
- Publication type:
- Article
Next-Generation BTK Inhibitor Highly Active in Relapsed or Refractory Mantle-Cell Lymphoma.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 1, p. 17
- By:
- Publication type:
- Article
Durable Responses to CAR T-Cell Therapy in B-Cell Lymphomas.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 1, p. 11
- By:
- Publication type:
- Article
Explosive Development of BCMA CAR T-Cell Therapies for Multiple Myeloma.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 1, p. 10
- By:
- Publication type:
- Article
Checkpoint Inhibitor a New Approach to Jump-Start a Waning Response to CAR T-Cell Therapy.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 1, p. 9
- By:
- Publication type:
- Article
High Incidence of Adverse Events Linked to Significant Economic Burden in Patients with Chronic Lymphocytic Leukemia.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 1, p. 1
- By:
- Publication type:
- Article
Checkpoint Inhibition Consolidation Therapy Promising in High-Risk Hematologic Malignancies.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 1, p. 1
- By:
- Publication type:
- Article
MURANO: Venetoclax-Rituximab at Fixed Duration Beats Chemoimmunotherapy in Relapsed/Refractory CLL.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 1, p. 1
- By:
- Publication type:
- Article
Rapid Progress in Aggressive Hematologic Malignancies Highlighted at ASH 2018.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 1, p. 1
- By:
- Publication type:
- Article